What is it about?
HIV-infected patients are usually evaluated by measuring peripheral CD4+ T lymphocyte counts, but they often have bone marrow damages. This study demonstrated using a mouse model that if bone marrow hematopoietic stem cells are armed with anti-HIV gene therapy, this may result in preserved bone marrow hematopoietic stem/progenitor cell counts.
Featured Image
Why is it important?
Many HIV-positive patients are suffering from hematological changes caused by bone marrow damage following infection. It is important to find good strategies to protect their bone marrow cells and hematopoietic potential.
Perspectives
In addition to the above results, this study also indicated that HIV infection could overdrive hematopoietic cell turnover to compensate for CD4+ cell loss, causing depletion of hematopoietic stem/progenitor cells. The suggestion may give further insights on how patients' bone marrow cells can be better protected from the disease.
Dr Tetsuo Tsukamoto
Read the Original
This page is a summary of: Transcriptional gene silencing limits CXCR4-associated depletion of bone marrow CD34+ cells in HIV-1 infection, AIDS, May 2018, Wolters Kluwer Health,
DOI: 10.1097/qad.0000000000001882.
You can read the full text:
Resources
Contributors
The following have contributed to this page
